Comprehensive Cancer Management Guidelines

Introduction to Cancer Care

A multidisciplinary team-based approach is the cornerstone of effective cancer management, integrating surgery, radiotherapy, systemic treatments, and supportive care to optimize patient outcomes in terms of morbidity, mortality, and quality of life, as recommended by the American Cancer Society and the European Society for Medical Oncology 1, 2

Cancer care should be delivered in specialized cancer units/centers by a multidisciplinary team consisting of medical oncologists, surgeons, radiation oncologists, radiologists, pathologists, and specialized nurses, according to the European Society for Medical Oncology 2
The cancer unit should have access to or be able to refer patients to plastic/reconstructive surgeons, psychologists, physiotherapists, and geneticists when appropriate, as suggested by the European Society for Medical Oncology 2
A specialized nurse or healthcare practitioner should be available to act as a patient navigator throughout the cancer journey, as recommended by the European Society for Medical Oncology 2

Comprehensive pathology reporting using standardized protocols is essential for quality cancer care, according to the College of American Pathologists and the National Comprehensive Cancer Network 3
Initial assessment should include determination of disease stage, estimation of recurrence risk, and evaluation of predictive biomarkers that guide treatment selection, as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 2, 3
Genetic counseling is recommended for patients at high risk for hereditary cancer syndromes, according to the National Comprehensive Cancer Network 3
Imaging studies should be selected based on cancer type and suspected extent of disease, potentially including CT, MRI, bone scans, and PET/PET-CT, as suggested by the European Society for Medical Oncology and the American Society of Clinical Oncology 4, 5

Treatment decisions should be based on tumor burden/location, tumor biology, patient age, menopausal status, general health status, and patient preferences, as recommended by the European Society for Medical Oncology 2
Age alone should not determine treatment recommendations but should be considered alongside other factors, according to the European Society for Medical Oncology 2
Fertility preservation options should be discussed with younger patients before initiating systemic treatments, as suggested by the European Society for Medical Oncology 2

Surgical approaches have shifted toward more conservative techniques when possible, with approximately 60-80% of breast cancers being amenable to breast conservation techniques, as reported by the European Society for Medical Oncology 2
Neoadjuvant therapy should be considered for certain cancer subtypes that are highly sensitive to chemotherapy, according to the European Society for Medical Oncology 2
Re-irradiation to limited areas may be considered in previously irradiated patients after careful risk-benefit assessment, as suggested by the European Society for Medical Oncology 4
Endocrine therapy is preferred for hormone receptor-positive disease unless rapid response is needed or endocrine resistance is suspected, according to the European Society for Medical Oncology 6
HER2-directed therapy should be offered early to all HER2-positive breast cancer patients, as recommended by the European Society for Medical Oncology 6

Rehabilitation assessment and interventions should be integrated into cancer care to address physical and cognitive impairments and manage treatment-related symptoms, as recommended by the American Cancer Society and the European Society for Medical Oncology 1
A prospective surveillance approach is recommended, with baseline measures of performance and function repeatedly monitored over time, according to the American Cancer Society and the European Society for Medical Oncology 1
Psychosocial support from trained professionals should be available at all stages of the cancer journey, as suggested by the European Society for Medical Oncology 7
Patient-reported outcomes should be regularly assessed to help evaluate treatment impact and monitor symptoms requiring intervention, according to the European Society for Medical Oncology 6

Follow-up after curative treatment should include regular clinical assessments to provide optimal palliation of symptoms and maintain quality of life, as recommended by the European Society for Medical Oncology 6
Imaging surveillance should be tailored to the cancer type and risk of recurrence, according to the American Society of Clinical Oncology and the European Society for Medical Oncology 5
Patients should be instructed to contact their physician immediately if symptoms suggestive of disease progression or treatment complications develop, as suggested by the European Society for Medical Oncology 6
Patients are at increased risk of developing second primary cancers and may benefit from appropriate screening, according to the American Society of Clinical Oncology and the European Society for Medical Oncology 5

Information on diagnosis and treatment options should be provided repeatedly, both verbally and in writing, in a comprehensive and easily understandable form, as recommended by the European Society for Medical Oncology 2
Patients should be actively involved in all management decisions, according to the European Society for Medical Oncology 2
Reliable, patient-centered information sources should be recommended, as suggested by the European Society for Medical Oncology 2
Patients need clear information about the purpose of different treatments, potential side effects, and impact on functional, emotional, and social well-being, according to the European Society for Medical Oncology 6

Administrative barriers can limit implementation of integrated models of care and should be addressed at the organizational level, as reported by the American Cancer Society and the European Society for Medical Oncology 1
Guideline implementation is often challenged by real-world clinical practice limitations including staffing, workforce knowledge, clinical workflows, and program sustainability, according to the American Cancer Society and the European Society for Medical Oncology 1
Patients may not receive appropriate rehabilitation services if functional assessments are not properly linked to referral pathways, as suggested by the American Cancer Society and the European Society for Medical Oncology 1
Monitoring response to treatment can be challenging in patients with non-measurable disease, according to the European Society for Medical Oncology 4